Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.
MiAlgae Ltd, founded in 2016 and based in Edinburgh, United Kingdom, specializes in producing microalgal products aimed at replacing fishmeal in livestock feeds. The company focuses on creating nutrient-rich microalgae, which are high in omega-3 fatty acids and proteins essential for aquaculture and other livestock. By utilizing wastewater remediation in their production process, MiAlgae implements a circular economy approach that lowers operating costs and enhances sustainability. Their innovative methodology not only provides a viable alternative to traditional fishmeal but also supports more sustainable practices in the livestock feed industry, which is valued at £340 billion globally.
Solasta Bio specializes in the development of environmentally friendly agricultural products focused on crop protection. The company offers a range of biological pesticides and neuropeptide-based insect control solutions designed to address the challenges posed by pests, including those resistant to traditional synthetic chemicals. By providing effective natural alternatives, Solasta Bio aims to assist farmers in managing pest populations while enhancing crop production sustainably and safely. Its innovative approach aligns with the growing global demand for effective and eco-conscious agricultural practices.
Metacarpal specializes in the development of innovative bionic prosthetic hands designed to enhance the quality of life for individuals with limb differences. Their pioneering technology features fully mechanical prostheses capable of variable grips, allowing users to effortlessly switch between different hand positions for various tasks. This adaptability ensures a secure grip on objects of varying shapes and sizes, complemented by a grip lock feature for added stability. By integrating intuitive control mechanisms reminiscent of body-powered devices, Metacarpal aims to provide users with a natural and responsive experience. In addition to serving individuals in developed regions, the company is committed to supplying prosthetics to underprivileged communities in the developing world, addressing a critical need for accessible assistive technology.
Nami Surgical provides robotic surgery technology solutions to enhance patient care while giving surgeons intuitive, high-performance moveable instruments.
Nebu-Flow is a manufacturer focused on developing advanced inhaled drug delivery systems for patients with respiratory disorders. The company specializes in innovative technology that controls droplet size to enhance deep lung deposition, facilitating effective drug delivery through inhalation. This technology not only targets existing formulations but also accommodates emerging therapeutics, including biologics, nanomedicines, and vaccines. By enabling injection-free systemic drug delivery, Nebu-Flow aims to improve treatment options for various respiratory, cardiovascular, and central nervous system conditions. The company is also dedicated to minimizing its environmental impact while ensuring its nebulizers remain user-friendly and high-performing.
Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.
Trojan Energy Limited, established in 2016 and headquartered in Stonehaven, United Kingdom, specializes in providing innovative charging infrastructure solutions for electric vehicles. The company focuses on the development of on-street flat and flush charging points, addressing the challenges faced by vehicle owners who lack access to off-street parking. This system allows drivers to park their vehicles in available street spaces and utilize an on-street charging lance, thereby enhancing the convenience and practicality of electric vehicle usage. Trojan Energy aims to support the widespread adoption of electric vehicles by ensuring that charging options are accessible to all, regardless of their parking situation.
Beta Bugs is an insect genetics company focused on developing high-performance breeds of Black Soldier Fly for insect farmers. The company's primary mission is to enhance the productivity of the insect protein sector, making it competitive with traditional feed ingredients such as fishmeal and soymeal. To achieve this, Beta Bugs operates a breeding program called HiPer-Fly® and runs an egg production site known as The Multiplier®, supplying its breeds to both UK and international markets. By leveraging biotechnology and breeding techniques, Beta Bugs aims to establish a sustainable protein source that converts food waste into high-quality protein for use in livestock, aquaculture, and pet feed, thereby providing an alternative to conventional feed sources. The company is headquartered at the Easter Bush Campus, collaborating with the Roslin Institute, a leader in animal genetics.
Microplate Dx is a developer of diagnostic technology focused on reducing fatalities from drug-resistant infections. As an award-winning spinout from the University of Strathclyde in Glasgow, the company aims to address the global health challenge of antimicrobial resistance. Microplate Dx's innovative solutions utilize highly sensitive biosensor electrodes, combined with miniaturized hydrogel deposits containing antibiotics specific to the infection being detected. Their medical diagnostic device provides a low-cost and accurate point-of-care alternative, enabling rapid antibiotic prescribing in under one hour. This approach enhances antibiotic stewardship and strives to manage the spread of antimicrobial resistance effectively.
Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.
Solasta Bio specializes in the development of environmentally friendly agricultural products focused on crop protection. The company offers a range of biological pesticides and neuropeptide-based insect control solutions designed to address the challenges posed by pests, including those resistant to traditional synthetic chemicals. By providing effective natural alternatives, Solasta Bio aims to assist farmers in managing pest populations while enhancing crop production sustainably and safely. Its innovative approach aligns with the growing global demand for effective and eco-conscious agricultural practices.
Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.
MiAlgae Ltd, founded in 2016 and based in Edinburgh, United Kingdom, specializes in producing microalgal products aimed at replacing fishmeal in livestock feeds. The company focuses on creating nutrient-rich microalgae, which are high in omega-3 fatty acids and proteins essential for aquaculture and other livestock. By utilizing wastewater remediation in their production process, MiAlgae implements a circular economy approach that lowers operating costs and enhances sustainability. Their innovative methodology not only provides a viable alternative to traditional fishmeal but also supports more sustainable practices in the livestock feed industry, which is valued at £340 billion globally.
Nebu-Flow is a manufacturer focused on developing advanced inhaled drug delivery systems for patients with respiratory disorders. The company specializes in innovative technology that controls droplet size to enhance deep lung deposition, facilitating effective drug delivery through inhalation. This technology not only targets existing formulations but also accommodates emerging therapeutics, including biologics, nanomedicines, and vaccines. By enabling injection-free systemic drug delivery, Nebu-Flow aims to improve treatment options for various respiratory, cardiovascular, and central nervous system conditions. The company is also dedicated to minimizing its environmental impact while ensuring its nebulizers remain user-friendly and high-performing.
Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.
Good-Loop converts advertising money into funding for social causes in a way that makes online advertising more effective, more rewarding and more ethical. We distribute video ads across our network of quality online publishers. The Good-Loop ad player will never auto-play or interrupt but if you choose to, you can opt-in to watch an advert and then donate 50% of the advertisers' money to your chosen social cause. But Good-Loop isn't just good for the world, it's also good for the advertisers' bottom line. The average completed view rate on YouTube is 30% and on Good-Loop it’s 61% – over double the engagement, for the same price. Good-Loop was part of the Collider Startup Accelerator Program 2017, and winner for their 2017 Demo Day - http://collider.io/
Talking Medicines Limited is a data technology company based in Glasgow, United Kingdom, that focuses on capturing and structuring patient feedback on medications. Its primary offering, the Medsmart application, collects insights on how and why patients take their medications. The company utilizes advanced artificial intelligence and natural language processing to analyze unstructured social feedback, providing pharmaceutical companies with deep insights into patient experiences. Through its PatientMetRx® platform, Talking Medicines enables clients to make data-driven marketing decisions by delivering comprehensive patient insights that enhance advertising effectiveness and improve health outcomes. Additionally, the company offers various services, including real-world persona data reports, digital focus group solutions, and custom analytics tailored to specific medicines. Founded in 2013 and rebranded from Virtual Genie Limited in 2015, Talking Medicines serves the pharmaceutical and healthcare sectors, aiming to revolutionize the industry by providing unprecedented access to patient voices.
Trojan Energy Limited, established in 2016 and headquartered in Stonehaven, United Kingdom, specializes in providing innovative charging infrastructure solutions for electric vehicles. The company focuses on the development of on-street flat and flush charging points, addressing the challenges faced by vehicle owners who lack access to off-street parking. This system allows drivers to park their vehicles in available street spaces and utilize an on-street charging lance, thereby enhancing the convenience and practicality of electric vehicle usage. Trojan Energy aims to support the widespread adoption of electric vehicles by ensuring that charging options are accessible to all, regardless of their parking situation.
EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.
Trojan Energy Limited, established in 2016 and headquartered in Stonehaven, United Kingdom, specializes in providing innovative charging infrastructure solutions for electric vehicles. The company focuses on the development of on-street flat and flush charging points, addressing the challenges faced by vehicle owners who lack access to off-street parking. This system allows drivers to park their vehicles in available street spaces and utilize an on-street charging lance, thereby enhancing the convenience and practicality of electric vehicle usage. Trojan Energy aims to support the widespread adoption of electric vehicles by ensuring that charging options are accessible to all, regardless of their parking situation.
Solasta Bio specializes in the development of environmentally friendly agricultural products focused on crop protection. The company offers a range of biological pesticides and neuropeptide-based insect control solutions designed to address the challenges posed by pests, including those resistant to traditional synthetic chemicals. By providing effective natural alternatives, Solasta Bio aims to assist farmers in managing pest populations while enhancing crop production sustainably and safely. Its innovative approach aligns with the growing global demand for effective and eco-conscious agricultural practices.
Cyan Forensics develops advanced technologies designed to assist law enforcement, social media platforms, and cloud service providers in identifying and blocking harmful content related to paedophilia and terrorism. By streamlining the examination process of consumer devices, Cyan Forensics significantly reduces the time required for police investigations, enhancing their ability to combat online threats effectively.
Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.
Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.
Trojan Energy Limited, established in 2016 and headquartered in Stonehaven, United Kingdom, specializes in providing innovative charging infrastructure solutions for electric vehicles. The company focuses on the development of on-street flat and flush charging points, addressing the challenges faced by vehicle owners who lack access to off-street parking. This system allows drivers to park their vehicles in available street spaces and utilize an on-street charging lance, thereby enhancing the convenience and practicality of electric vehicle usage. Trojan Energy aims to support the widespread adoption of electric vehicles by ensuring that charging options are accessible to all, regardless of their parking situation.
Cyan Forensics develops advanced technologies designed to assist law enforcement, social media platforms, and cloud service providers in identifying and blocking harmful content related to paedophilia and terrorism. By streamlining the examination process of consumer devices, Cyan Forensics significantly reduces the time required for police investigations, enhancing their ability to combat online threats effectively.
EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.
Talking Medicines Limited is a data technology company based in Glasgow, United Kingdom, that focuses on capturing and structuring patient feedback on medications. Its primary offering, the Medsmart application, collects insights on how and why patients take their medications. The company utilizes advanced artificial intelligence and natural language processing to analyze unstructured social feedback, providing pharmaceutical companies with deep insights into patient experiences. Through its PatientMetRx® platform, Talking Medicines enables clients to make data-driven marketing decisions by delivering comprehensive patient insights that enhance advertising effectiveness and improve health outcomes. Additionally, the company offers various services, including real-world persona data reports, digital focus group solutions, and custom analytics tailored to specific medicines. Founded in 2013 and rebranded from Virtual Genie Limited in 2015, Talking Medicines serves the pharmaceutical and healthcare sectors, aiming to revolutionize the industry by providing unprecedented access to patient voices.